Formulation Development
AMRI Becomes Curia
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is…
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and…
Strathclyde University conclude that membrane technology could revolutionize vaccine and therapeutics production
Whilst paying tribute to to the hugely impressive efforts of those who reconfigured existing equipment at speed into a "Generation 1" manufacturing process for mRNA…
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading global provider of advanced delivery…
Curia, the former AMRI, to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities
One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement…
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence…
Cyclerion Therapeutics & Beacon Biosignals Announce Expanded Strategic Partnership
Cyclerion Therapeutics, Inc. and Beacon Biosignals recently announced an extended and expanded strategic partnership between the two companies. This collaboration is expected to identify disease-relevant…
Roquette Earns USDA Certified Biobased Product Label for BIOSUCCINIUM
Roquette recently announced it has earned the US Department of Agriculture (USDA) Certified Biobased Product label. The product, BIOSUCCINIUM® succinic acid, is now able to…
Evaxion Biotech Reports Data From Phase 1/2a Trials of EVX-01 & EVX-02
Evaxion Biotech A/S recently announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of…
Ensysce Biosciences Receives Notice of Award for Year 3 of Multi-Year NIDA Grant for the Clinical Development of its Next-Generation Opioid Products With Overdose Protection
Ensysce Biosciences, Inc. recently announced receipt of the third year award of a multi-year grant from the National Institute on Drug Abuse (NIDA). This award…
Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US FDA. Breakthrough Therapy Designation…
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase 1 trial of AKS-452, its…
LGM Pharma Launches New Stand-Alone Analytical Services Offering for Drug Developers & Manufacturers
LGM Pharma, a long-time leader in API sourcing, completed a transformational acquisition last year of long-established CDMO NexGen Pharma. Among the many new capabilities LGM…
Brickell Biotech Announces Final Patient Completed in First US Phase 3 Pivotal Clinical Study & Patient Enrollment Completed in Second US Phase 3 Pivotal Clinical Study
Brickell Biotech, Inc. recently announced the final patient has completed the Phase 3 pivotal Cardigan I study, and that all planned patients have been enrolled in the Phase 3 pivotal Cardigan II study…..
BioAegis Awarded BARDA Contract to Advance Development of a Novel Host-Directed Human Protein for Patients With Sepsis & Severe Infection
BioAegis Therapeutics Inc. recently announced it was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, to further….
Apellis & Beam Therapeutics Enter Exclusive Research Collaboration
Apellis Pharmaceuticals, Inc. and Beam Therapeutics Inc. recently announced an exclusive 5-year research collaboration focused on the use of Beam’s proprietary base editing technology to discover new….
Encoded Therapeutics Partners With Genedata to Accelerate AAV-Based Gene Therapy Development
Genedata recently announced that Encoded Therapeutics has chosen Genedata Bioprocess to digitalize their proprietary gene therapy R&D technology…..
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative & Biothreat Pathogens
Entasis Therapeutics Holdings Inc. recently announced the presentation of preclinical data on ETX0462, a novel, first-in-class, diazabicyclooctane with antimicrobial activity against multidrug-resistant (MDR) Gram-negative and…
Atea’s Oral Antiviral Drug Candidate Reduces Viral Replication in Hospitalized Patients With COVID-19 in Phase 2 Interim Analysis
Atea Pharmaceuticals, Inc. recently announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-moderate COVID-19. Roche and Atea…
Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients With Chronic Rhinosinusitis
Lyra Therapeutics, Inc. recently announced positive topline results from the company’s pharmacokinetic (PK) study of LYR-210. Data obtained from the study are supportive of LYR-210’s…